Journal: BioMed Research International

Article Title: SNP rs8099917 in Gene IL28B Might Be Associated with Risk of Chronic Infection by HCV but Not with Response to Treatment

doi: 10.1155/2014/748606

Figure Lengend Snippet: Genotypic and allelic frequencies of SNP rs12979860 and rs8099917 in gene IL28B in individuals with chronic hepatitis C virus infection and the control group, Belém, 2012.

Article Snippet: The rs12979860 target sequence was sent to the Applied Biosystems company, which designed the following primer and probe sequences: 5′-GCC TGT CGT GTA CTG AAC CA-3′ (forward), 5′-GCG CGG AGT TGC AAT TCA AC-3′ (reverse), 5′VIC-TGG TTC GCG CTT C-3′ (allele C probe), and 5′FAM-CTG GTT CAC GCC TTC-3′ (allele T probe).

Techniques: Virus, Infection, Control

Journal: BioMed Research International

Article Title: SNP rs8099917 in Gene IL28B Might Be Associated with Risk of Chronic Infection by HCV but Not with Response to Treatment

doi: 10.1155/2014/748606

Figure Lengend Snippet: Association of SNPs rs12979860 and rs8099917 with sustained virologic response in individuals with chronic hepatitis C treated with PEG-IFN and RBV.

Article Snippet: The rs12979860 target sequence was sent to the Applied Biosystems company, which designed the following primer and probe sequences: 5′-GCC TGT CGT GTA CTG AAC CA-3′ (forward), 5′-GCG CGG AGT TGC AAT TCA AC-3′ (reverse), 5′VIC-TGG TTC GCG CTT C-3′ (allele C probe), and 5′FAM-CTG GTT CAC GCC TTC-3′ (allele T probe).

Techniques:

Journal: Cancer Cell International

Article Title: Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells

doi: 10.1186/s12935-014-0142-4

Figure Lengend Snippet: Impact of PXR activation in DOX and PTX treated cells. (A) PXR mRNA expression with the treatment of DOX and PTX at 0, 4, 8, 12, 24, 36, 48 h. (B) Western blot analysis of PXR with 24 h treatment of DOX and PTX. **, p < 0.01 (n = 3). (C) RT-PCR analysis of PXR mRNA in PTX only (PTX) or treated cells exposed to transfection conditions in the absence of siRNA (mock) or cells transfected with non-targeting (NC) or PXR-specific siRNA (siRNA). (D) Comparison of MDR1 mRNA expression in the cells exposed to transfection conditions with 8 h/36 h DOX and PTX treatment. **, p < 0.01 (n = 3). (E) Rho-123 fluorescence ratio in the cells exposed to transfection conditions with 8 h/36 h DOX and PTX treatment. *, p < 0.05 (n = 3).

Article Snippet: The siRNA sequence targeting human PXR gene and the negative control that consisted of a non-complementary sequence were developed by GenePharma (Shanghai, China).

Techniques: Activation Assay, Expressing, Western Blot, Reverse Transcription Polymerase Chain Reaction, Transfection, Comparison, Fluorescence